Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Cartesian Therapeutics (RNAC) over the last 10 years, with Q3 2025 value amounting to $5.6 million.

  • Cartesian Therapeutics' Other Non-Current Assets rose 23259.44% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 23259.44%. This contributed to the annual value of $1.7 million for FY2024, which is 2120.55% up from last year.
  • As of Q3 2025, Cartesian Therapeutics' Other Non-Current Assets stood at $5.6 million, which was up 23259.44% from $5.6 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Other Non-Current Assets registered a high of $6.1 million during Q1 2025, and its lowest value of $1.3 million during Q4 2022.
  • Over the past 5 years, Cartesian Therapeutics' median Other Non-Current Assets value was $1.4 million (recorded in 2021), while the average stood at $2.1 million.
  • Per our database at Business Quant, Cartesian Therapeutics' Other Non-Current Assets crashed by 1393.75% in 2023 and then skyrocketed by 33957.88% in 2025.
  • Over the past 5 years, Cartesian Therapeutics' Other Non-Current Assets (Quarter) stood at $1.4 million in 2021, then decreased by 4.93% to $1.3 million in 2022, then grew by 5.03% to $1.4 million in 2023, then increased by 21.21% to $1.7 million in 2024, then skyrocketed by 232.59% to $5.6 million in 2025.
  • Its last three reported values are $5.6 million in Q3 2025, $5.6 million for Q2 2025, and $6.1 million during Q1 2025.